Maxizyme Technology

  • Mayu Iyo
  • Hiroaki Kawasaki
  • Kazunari Taira
Part of the Methods in Molecular Biology™ book series (MIMB, volume 252)

Abstract

Ribozymes are small and versatile nucleic acids that can cleave RNAs at specific sites. These molecules have great potential to be used as effective gene-therapeutic agents. However, because of the limitation for cleavable sequences within the target mRNA, in some cases conventional ribozymes have failed to exhibit precise cleavage specificity. A maxizyme is the dimer of minimized ribozymes (minizymes), which can specifically cleave two distinct target sites. The maxizyme also has an allosteric function in that it can form an active conformation and cleave the two target sites only when it recognizes two distinct target sites. We demonstrated previously that an allosterically controllable maxizyme was a powerful tool in the disruption of an abnormal chimeric RNA (bcr-abl) in cells and in mice. Furthermore, more than five custom-designed maxizymes have clearly demonstrated these allosteric functions in vitro and in vivo. Thus, maxizyme technology is not limited to one specific case, but may have broad general applicability in molecular biology and in molecular gene therapy.

Keywords

Vortex Adenosine Electrophoresis MgCl2 Ampicillin 

Reference

  1. 1.
    Shimayama, T., Nishikawa, S., and Taira, K. (1995) Generality of the NUX rule: kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes. Biochemistry 34, 3649–3654.PubMedCrossRefGoogle Scholar
  2. 2.
    Gesteland, R. F., Cech, T. R., and Atkins, J. F. (1999) The RNA World, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.Google Scholar
  3. 3.
    Kawasaki, H., Eckner, R., Yao, T. P., Taira, K., Chiu, R., Livingston, D. M., et al. (1998) Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 393, 284–289.PubMedCrossRefGoogle Scholar
  4. 4.
    Kawasaki, H., Suyama, E., Iyo, M., and Taira, K. (2003) siRNAs generated by recombinant human Dicer induce specific and significant but target site-independent gene silencing in human cells. EMBO J., in press.Google Scholar
  5. 5.
    Krupp, G. and Gaur, R. K. (eds.) (2000) Ribozyme, Biochemistry and Biotechnology. Eaton Publishing Natick, MA.Google Scholar
  6. 6.
    Amontov, S. V. and Taira, K. (1996) Hammerhead minizymes with high cleavage activity: a dimeric structure as the active conformation of minizymes. J. Am. Chem. Soc. 118, 1624–1628.CrossRefGoogle Scholar
  7. 7.
    Kuwabara, T., Warashina, M., Orita, M., Koseki, S., Ohkawa, J., and Taira, K. (1998) Formation in vitro and in cells of a catalytically active dimer by tRNAVal-driven short ribozymes. Nature Biotechnol. 16, 961–965.CrossRefGoogle Scholar
  8. 8.
    Kuwabara, T., Warashina, M., Nakayama, A., Ohkawa, J., and Taira, K. (1999) Novel tRNAVal-heterodimeric maxizymes with high potential as gene-inactivating agents: Simultaneous cleavage at two sites in HIV-1 tat mRNA in cultured cells. Proc. Natl. Acad. Sci. USA 96, 1886–1891.PubMedCrossRefGoogle Scholar
  9. 9.
    Tanabe, T., Takata, I., Kuwabara, T., Warashina, M., Kawasaki, H., Tani, K., et al. (2000) Maxizymes, novel allosterically controllable ribozymes can be designed to cleave various substrates. Biomacromology 1, 108–111.CrossRefGoogle Scholar
  10. 10.
    Tanabe, T., Kuwabara, T., Warashina, M., Tani, K., Taira, K., and Asano, S. (2000) Oncogene inactivation in a mouse model: tissue invasion by leukaemic cells is stalled by loading them with a designer ribozyme. Nature 406, 473,474.Google Scholar
  11. 11.
    Surekha, M., Zinged (2001) Cancer genes. Curr. Sci. 81, 5.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2004

Authors and Affiliations

  • Mayu Iyo
    • 1
  • Hiroaki Kawasaki
    • 1
  • Kazunari Taira
    • 1
  1. 1.Department of Chemistry and Biotechnology, School of EngineeringThe University of TokyoTokyoJapan

Personalised recommendations